Cointime

Spero Therapeutics

company

About

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

  • 1 - 10

Highlights

Total Funding Amount
$40.25M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$40M
Industries
Biotechnology,Medical Device,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$40.25M
Spero Therapeutics has raised a total of $40.25M in funding over 2 rounds. Their latest funding was raised on Jun 30, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 30, 2021 Post-IPO Equity $40M 1 Pfizer — Detail
Feb 8, 2021 Grant $256K 1 National Science Foundation — Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Spero Therapeutics is funded by 2 investors. Pfizer and National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
Pfizer Yes Post-IPO Equity
National Science Foundation Yes Grant
Cointime
Содержание
компания